IMTXWimmatics biotechnologies GmbH

—Mkt Cap: —P/E: —456d ago

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developi…

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)144.15M $

Gross Profit-13.73M $

Net Income (TTM)-196.45M $

Revenue/Share1.293 USD

Last Price—

Fiscal Year End—

MR Quarter—

Employees646

CountryUS

Sector—

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.00

EPS (TTM)—

EPS (Forward)—

52W Range

—

52W High—

52W Low—

Profitability

Gross Margin-9.53%

Oper. Margin-190.37%

EBITDA Margin-35.84%

Profit Margin-407.01%

ROE-40.58%

ROA-34.93%

Growth

Revenue Growth-38.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-176.63M $

CapEx (TTM)6.80M $

FCF Margin-81.72%

FCF Yield—

Net Debt-525.37M $

Net Debt/EBITDA10.17

Balance Sheet

Debt/Equity0.03

Current Ratio10.28

Quick Ratio9.87

Book Value/Sh4.415 USD

Cash/Share4.474 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float58.79M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta0.82

S&P 52W Chg16.25%

Avg Vol (30d)—

Avg Vol (10d)—

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—